Xiaolong Qi is a hepatologist at the Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS), Hepatology Center, Nanfang Hospital, Southern Medical University. He obtained his MD from Tongji University School of Medicine, and completed a postdoctoral fellow in hepatology at Harvard Medical School. His research interest and clinical practice focuses on the patient-oriented clinical and translational research about the diagnosis and monitoring of advanced chronic liver disease, particularly the non-invasive and invasive assessment for portal hypertension.
His professional activities have been notable, especially as the founder and chair of CHESS leading the Chinese consensus on the non-invasive and invasive assessment for portal hypertension, chair of CHESS Digital Medicine and Translational Research Center, Lanzhou University; deputy chair of Portal Hypertension Subcommittee, Chinese Research Hospital Association for Liver Diseases. In 2018, he was selected as the president of APASL Single Topic Conference 2020 on Portal Hypertension, and the member of AASLD Portal Hypertension Global Subcommittee.
Xiaolong Qi is Advisory board member of EBioMedicine, author/co-author of over 80 peer-reviewed original and review articles in The Lancet Gastroenterology & Hepatology, Gut, Science Translational Medicine, Journal of Hepatology, Trends in Biotechnology, Annals of Surgery, etc., and his research finding was highlighted and promoted by The Lancet Oncology. He believes the non-invasive assessment will play a significant role in hepatology, and is willing to lead CHESS collaborating with international physicians and scientists together to move the field of diagnosis and monitoring of portal hypertension forward.